VOR vs. IMNM, SNDX, CMRX, CDMO, AVXL, SION, QURE, AVBP, CRON, and XERS
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Immunome (IMNM), Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Anavex Life Sciences (AVXL), Sionna Therapeutics (SION), uniQure (QURE), ArriVent BioPharma (AVBP), Cronos Group (CRON), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs. Its Competitors
Vor Biopharma (NYSE:VOR) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.
Vor Biopharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Vor Biopharma has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. Vor Biopharma's return on equity of 0.00% beat Immunome's return on equity.
Vor Biopharma has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Vor Biopharma presently has a consensus price target of $5.63, indicating a potential upside of 110.81%. Immunome has a consensus price target of $23.33, indicating a potential upside of 168.51%. Given Immunome's stronger consensus rating and higher possible upside, analysts clearly believe Immunome is more favorable than Vor Biopharma.
In the previous week, Vor Biopharma had 8 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Vor Biopharma and 2 mentions for Immunome. Immunome's average media sentiment score of 0.70 beat Vor Biopharma's score of 0.24 indicating that Immunome is being referred to more favorably in the news media.
97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 2.9% of Vor Biopharma shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Vor Biopharma beats Immunome on 8 of the 13 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 7/8/2025 by MarketBeat.com Staff
Free VOR Stock Alerts